Drugs / Ifetroban
Ifetroban
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials · 1 met primary | ||||||
| Phase 2 | NCT05571059 | Jan 2024 → Jan 2027 expected | idiopathic pulmonary fibrosis | Cumberland Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT03340675 | Oct 2020 → Mar 2024 | Duchenne muscular dystrophy, dilated cardiomyopathy | Cumberland Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03694249 | Dec 2018 → Apr 2025 | cancer | Vanderbilt-Ingram Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT03028350 | Jul 2017 → Apr 2023 | aspirin-induced respiratory disease | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02802228 | Mar 2017 → Jul 2018 | cirrhosis of liver, portal hypertension | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02682511 | Jan 2017 → Jun 2026 overdue | diffuse cutaneous systemic sclerosis, limited systemic sclerosis | Cumberland Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01436500 | Oct 2011 → Jun 2015 | hepatorenal syndrome | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT03962855 Comparator | Sep 2019 → Nov 2022 | vascular ectasia | Jeffrey Rade | Completed | No outcome recorded |
| Phase 2 | NCT03326063 Comparator | Apr 2018 → Mar 2022 | aspirin-induced respiratory disease, asthma, nasal polyps, and aspirin intolerance, nasal cavity polyp | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02216357 Comparator | Aug 2014 → Jan 2016 | aspirin-induced respiratory disease | Cumberland Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-03-18 | Cumberland Pharmaceuticals | Results Ifetroban Shows Promise in Slowing Cardiac Decline in Duchenne Muscular Dystrophy cumberlandpharma.com ↗
Recent findings from the randomized, placebo-controlled phase 2 FIGHT DMD trial (NCT03340675) demonstrated that high-dose ifetroban (Cumberland Pharmaceuticals), an oral thromboxane prostanoid receptor (TPr) antagonist, may help slow the progression of cardiomyopathy (CM) in patients with Duchenne muscular dystrophy (DMD). |
| 2025-03-12 | Cumberland Pharmaceuticals | Results Potential therapeutic for Duchenne muscular dystrophy takes step forward cumberlandpharma.com ↗ |
| 2025-02-10 | Cumberland Pharmaceuticals | Results Cumberland Pharmaceuticals Reports Promising Ifetroban Results for DMD Patients cumberlandpharma.com ↗
Cumberland Pharmaceuticals, a specialty pharmaceutical company has reported encouraging top-line findings from its Phase 2 FIGHT DMD trial. |
| 2025-02-04 | Cumberland Pharmaceuticals | Results Cumberland Pharmaceuticals Stock Soars cumberlandpharma.com ↗ |
| 2025-02-04 | Cumberland Pharmaceuticals | Results Cumberland's Duchenne Drug Improves Blood Flow From Heart In Phase 2 Trial cumberlandpharma.com ↗
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, hitting the main goal of a phase 2 trial. |
| 2025-02-04 | Cumberland Pharmaceuticals | Results Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease cumberlandpharma.com ↗
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. |
| 2024-11-08 | Cumberland Pharmaceuticals | Regulatory FDA Grants Orphan Drug Designation to lfetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy cumberlandpharma.com ↗
The FDA granted orphan drug designation (ODD) and rare pediatric disease (RPD) designation to ifetroban, a thromboxane-prostanoid receptor (TPr) antagonist, for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), according to a news release from Cumberland Pharmaceuticals.1 |
All press releases naming this drug 8 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ifetroban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02682511 ↗ |
| Known as | BMS-180291 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301673 ↗ |
| Known as | BMS-180291-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301673 ↗ |
| Known as | Ifetroban sodium | “Ifetroban sodium injectable, diluted in sterile water with 5% dextrose” NCT01436500 ↗1“Drug: Ifetroban Sodium” NCT05571059 ↗ |
| Action | Inhibit | “thromboxane prostanoid receptor antagonist” NCT02802228 ↗ |
| Modality | Small molecule | — CHEMBL3301673 ↗ |
| Route | Intravenous | “60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days” NCT01436500 ↗ |